Is the absolute value of O6-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

Journal of Neurosurgery

Volumn 121, Issue 4, 2014, Pages 818-826

  Tanaka, Satoshi ^a   Akimoto, Jiro ^b   Narita, Yoshitaka ^c   Oka, Hidehiro ^d   Tashiro, Takashi ^e  

^a Tokyo West Tokushukai Hospital   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Hachioji Medical Center   (Japan)

Author keywords

Glioblastoma; MGMT; MRNA; Oncology; Real time RT PCR; Temozolomide

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

6 O METHYLGUANINE DNA METHYLTRANSFERASE GENE; ADULT; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMISTRY; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PROGNOSIS;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84907877949     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.6.JNS132535     Document Type: Article

References (40)

1. Aldea C, Alvarez CP, Folgueira L, Delgado R, Otero JR: Rapid detection of herpes simplex virus DNA in genital ulcers by real-Time PCR using SYBR green I dye as the detection signal. J Clin Microbiol 40: 1060-1062, 2002
2. Anderson E, Grant R, Lewis SC, Whittle IR: Randomized Phase III controlled trials of therapy in malignant glioma: Where are we after 40 years? Br J Neurosurg 22: 339-349, 2008
3. Baysan M, Bozdag S, Cam MC, Kotliarova S, Ahn S, Walling J, et al: G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS ONE 7: E47839, 2012
4. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8: 2725-2734, 2002
5. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, et al: Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: Use with caution. Mod Pathol 26: 922-929, 2013
6. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479, 1998
7. Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, et al: Recurrent high-grade glioma treated with bevacizumab: Prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115: 267-276, 2013
8. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
9. 6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671, 2000
10. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131, 2009
11. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999
12. Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y, et al: Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11: 348-356, 2009
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005
14. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996
15. 6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6: E17156, 2011
16. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148, 2011
17. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
18. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, et al: Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 117: 1721-1730, 2011
19. Mullah B, Livak K, Andrus A, Kenney P: Efficient synthesis of double dye-labeled oligodeoxyribonucleotide probes and their application in a real time PCR assay. Nucleic Acids Res 26: 1026-1031, 1998
20. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 37: 897-906, 2007
21. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al: A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Clinical article. J Neurosurg 116: 341-345, 2012
22. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al: IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65: 7573-7579, 2005
23. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010
24. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, et al: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-491, 1988
25. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 2: 187-193, 1984
26. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 53: 3416-3420, 1993
27. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
28. 6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-Time reverse-Transcription polymerase chain-reaction. Oncol Rep 20: 165-171, 2008
29. Tanaka S, Kamitani H, Amin MR, Watanabe T, Oka H, Fujii K, et al: Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drugresistance genes. J Neurooncol 46: 157-171, 2000
30. 6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-Time quantitative RTPCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72, 2003
31. 6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. Oncol Rep 14: 1275-1280, 2005
32. 6-methylguanine-DNA methyltransferase gene messenger RNA in gliomas by means of real-Time RTPCR and clinical response to nitrosoureas. Cell Mol Neurobiol 25: 1067-1071, 2005
33. 6-Alkylguanine. Proc Natl Acad Sci U S A 87: 686-690, 1990
34. 6-Alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011, 2003
35. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, et al: Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8: 196-201, 2002
36. Warren L, Bryder D, Weissman IL, Quake SR: Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR. Proc Natl Acad Sci U S A 103: 17807-17812, 2006
37. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, et al: Personalized care in neuro-oncology coming of age: Why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 14 Suppl 4: Iv100-iv108, 2012
38. Yoshida J, Kajita Y, Wakabayashi T, Sugita K: Long-Term follow-up results of 175 patients with malignant glioma: Importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) 127: 55-59, 1994
39. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17: 2762-2771, 1999
40. Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, et al: MiR-181d: A predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol 14: 712-719, 2012